share_log

Apollomics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apollomics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apollomics | 6-K：外国发行人报告
美股SEC公告 ·  05/08 16:11
Moomoo AI 已提取核心信息
On May 6, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced the entry into PIPE Subscription Agreements with certain accredited investors, with the closing expected on May 8, 2024. The company will issue 19,166,666 Class A ordinary shares at $0.30 each, aiming to raise $5.75 million before fees and expenses. The funds are intended for pipeline programs, general corporate purposes, and working capital. Additionally, Apollomics appointed Dr. Bob Lin to its board of directors and announced the resignation of Dr. Jonathan Wang from the board for personal reasons. The company emphasized that Dr. Wang's departure was not due to any disagreements with company operations or practices. Apollomics plans to file a registration statement with the SEC for the resale of the PIPE shares within thirty days post-closing. The securities offered in the PIPE are not registered under the Securities Act of 1933 and are subject to customary closing conditions.
On May 6, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced the entry into PIPE Subscription Agreements with certain accredited investors, with the closing expected on May 8, 2024. The company will issue 19,166,666 Class A ordinary shares at $0.30 each, aiming to raise $5.75 million before fees and expenses. The funds are intended for pipeline programs, general corporate purposes, and working capital. Additionally, Apollomics appointed Dr. Bob Lin to its board of directors and announced the resignation of Dr. Jonathan Wang from the board for personal reasons. The company emphasized that Dr. Wang's departure was not due to any disagreements with company operations or practices. Apollomics plans to file a registration statement with the SEC for the resale of the PIPE shares within thirty days post-closing. The securities offered in the PIPE are not registered under the Securities Act of 1933 and are subject to customary closing conditions.
2024年5月6日，处于临床阶段的生物制药公司Apollomics Inc. 宣布与某些合格投资者签订PIPE认购协议，预计将于2024年5月8日结束。该公司将以每股0.30澳元的价格发行19,1666股A类普通股，目标是在扣除费用和支出前筹集575万澳元。这些资金用于管道计划、一般公司用途和营运资金。此外，Apollomics任命鲍勃·林博士为董事会成员，并宣布王乔纳森博士因个人原因辞去董事会职务。该公司强调，王博士的离职不是由于与公司运营或实践有任何分歧。Apollomics计划在收盘后三十天内向美国证券交易委员会提交一份关于转售PIPE股票的注册声明。PIPE提供的证券未根据1933年《证券法》注册，并受惯例成交条件的约束。
2024年5月6日，处于临床阶段的生物制药公司Apollomics Inc. 宣布与某些合格投资者签订PIPE认购协议，预计将于2024年5月8日结束。该公司将以每股0.30澳元的价格发行19,1666股A类普通股，目标是在扣除费用和支出前筹集575万澳元。这些资金用于管道计划、一般公司用途和营运资金。此外，Apollomics任命鲍勃·林博士为董事会成员，并宣布王乔纳森博士因个人原因辞去董事会职务。该公司强调，王博士的离职不是由于与公司运营或实践有任何分歧。Apollomics计划在收盘后三十天内向美国证券交易委员会提交一份关于转售PIPE股票的注册声明。PIPE提供的证券未根据1933年《证券法》注册，并受惯例成交条件的约束。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息